Ian N. Olver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ian N. Olver has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Jaklin A. Eliott
University of Adelaide
2 shared publications- Jaklin Eliott
School of Public Health, Adelaide University, Level 4 Rundle Mall Plaza, 50 Rundle Mall, Adelaide, SA, 5000, Australia.
2 shared publications A. Boland
1 shared publicationA. McDonald
1 shared publication- Alex Molassiotis
College of Arts, Humanities and Education, University of Derby, Derby, United Kingdom
1 shared publication Andrew Dutney
1 shared publication
Latest Publications
- 3 August 2014
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 23 (1) , 251-252
Assessing the burden and management of chemotherapy induced emesis in the Asia/Pacific region
- 3 August 2014
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 23 (1) , 251-252
Assessing the burden and management of chemotherapy induced emesis in the Asia/Pacific region
- Open Access
- 8 May 2014
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 22 (10) , 2749-2756
A qualitative study investigating chemotherapy-induced nausea as a symptom cluster
The prevention of chemotherapy-induced vomiting has been improved by antiemetics, but nausea remains problematic. This study explores the concept that this is partly because patients use the term nausea to describe a cluster of symptoms. A total of 42 cancer patients currently being treated (n = 21) or at least 6 months of past treatment (median 3.5 years; n = 21) with experience of chemotherapy-induced nausea consented to semi-structured interviews about nausea, which were transcribed and analysed. There were 24 females and 18 males. The nature, number, location, duration and intensity of experiences described as nausea varied. Physical and psychological symptoms included dry retching, vomiting, anorexia, indigestion, change of taste, dizziness, bloating, reflux, inability to concentrate, fatigue and restlessness. Patients located nausea in sites ranging from the head/neck, sternum and mid and lower abdomen to the whole body. Some patients identified symptoms as part of the experience of nausea, and others described symptoms associated with nausea but separate from it. For most, distinguishing features of chemotherapy-induced (as opposed to other) nausea were its constant presence over time, fatigue and emotional associations with the cancer diagnosis. Triggers varied and included food (smells), negative emotions including anxiety, movement, smells (e.g., hand cream, cleaning products), treatment-related events, tooth brushing and mentioning nausea. Prescribed antiemetics were consistently noted as reducing the intensity of, but for many, not completely alleviating, nausea. Distraction and relaxation were preferred management techniques. Control of nausea will require treating the particular cluster of symptoms which a patient is experiencing as nausea.
- 8 May 2014
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 22 (10) , 2749-2756
Open AccessA qualitative study investigating chemotherapy-induced nausea as a symptom cluster
The prevention of chemotherapy-induced vomiting has been improved by antiemetics, but nausea remains problematic. This study explores the concept that this is partly because patients use the term nausea to describe a cluster of symptoms. A total of 42 cancer patients currently being treated (n = 21) or at least 6 months of past treatment (median 3.5 years; n = 21) with experience of chemotherapy-induced nausea consented to semi-structured interviews about nausea, which were transcribed and analysed. There were 24 females and 18 males. The nature, number, location, duration and intensity of experiences described as nausea varied. Physical and psychological symptoms included dry retching, vomiting, anorexia, indigestion, change of taste, dizziness, bloating, reflux, inability to concentrate, fatigue and restlessness. Patients located nausea in sites ranging from the head/neck, sternum and mid and lower abdomen to the whole body. Some patients identified symptoms as part of the experience of nausea, and others described symptoms associated with nausea but separate from it. For most, distinguishing features of chemotherapy-induced (as opposed to other) nausea were its constant presence over time, fatigue and emotional associations with the cancer diagnosis. Triggers varied and included food (smells), negative emotions including anxiety, movement, smells (e.g., hand cream, cleaning products), treatment-related events, tooth brushing and mentioning nausea. Prescribed antiemetics were consistently noted as reducing the intensity of, but for many, not completely alleviating, nausea. Distraction and relaxation were preferred management techniques. Control of nausea will require treating the particular cluster of symptoms which a patient is experiencing as nausea.
- 21 April 2014
- Published by AMPCo in Medical Journal of Australia
- Vol. 200 (7) , 368-369
Linking data to improve health outcomes
Click on the article title to read more.
- 21 April 2014
- Published by AMPCo in Medical Journal of Australia
- Vol. 200 (7) , 368-369
Linking data to improve health outcomes
Click on the article title to read more.
- 3 March 2014
- Published by AMPCo in Medical Journal of Australia
- Vol. 200 (4) , 201-202
Opting in for opt‐out consent
- 3 March 2014
- Published by AMPCo in Medical Journal of Australia
- Vol. 200 (4) , 201-202
Opting in for opt‐out consent
- 18 November 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (10) , 639-640
Lung cancer: let's try for prevention and cure
- 18 November 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (10) , 639-640
Lung cancer: let's try for prevention and cure
- 4 November 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (9) , 569-570
It is time for clinical guidelines to enter the digital age
Clinical guidelines can be easily updated with new evidence, continuously reviewed and widely disseminated if they are presented online on a MediaWiki platform which provides a collaborative website, similar to Wikipedia.
- 4 November 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (9) , 569-570
It is time for clinical guidelines to enter the digital age
Clinical guidelines can be easily updated with new evidence, continuously reviewed and widely disseminated if they are presented online on a MediaWiki platform which provides a collaborative website, similar to Wikipedia.
- 1 October 2013
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (11) , 1040-1042
Challenges of accessing cancer medicines in Australia
- 1 October 2013
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (11) , 1040-1042
Challenges of accessing cancer medicines in Australia
- 1 April 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 198 (6) , 300-301
Early success for Australia's bowel screening program: let's move it along
- 1 April 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 198 (6) , 300-301
Early success for Australia's bowel screening program: let's move it along
- 18 March 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 198 (5) , 254-255
Forming networks for research: proposal for an Australian clinical trials alliance
- 18 March 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 198 (5) , 254-255
Forming networks for research: proposal for an Australian clinical trials alliance
- 30 December 2012
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 21 (6) , 1561-1568
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy.
- 30 December 2012
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 21 (6) , 1561-1568
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy.